{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:41:40Z","timestamp":1758148900382,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002456","name":"Chonnam National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002456","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019780","name":"Chonnam National University Hwasun Hospital","doi-asserted-by":"publisher","award":["HCRI 24022"],"award-info":[{"award-number":["HCRI 24022"]}],"id":[{"id":"10.13039\/501100019780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prnil.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T21:37:48Z","timestamp":1743025068000},"page":"174-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The prevalence of dyslipidemia in patients with prostate cancer"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8072-3629","authenticated-orcid":false,"given":"Tae Hyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Gyeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Seok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eu","family":"Chang Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taek Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Deuk","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4864-8175","authenticated-orcid":false,"given":"Seung Il","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.prnil.2021.02.002","article-title":"Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?","volume":"10","author":"Shim","year":"2022","journal-title":"Prostate Int"},{"issue":"17","key":"10.1016\/j.prnil.2025.03.005_bib3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/jnci\/djs299","article-title":"Temporal trends in cause of death among Swedish and US men with prostate cancer","volume":"104","author":"Epstein","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.prnil.2025.03.005_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4111\/icu.20230103","article-title":"A review of the objective cognitive function measurements in males receiving hormonal therapy for prostate cancer","volume":"64","author":"Neerhut","year":"2023","journal-title":"Investig Clin Urol"},{"issue":"4","key":"10.1016\/j.prnil.2025.03.005_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.prnil.2024.07.004","article-title":"Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Kyaw","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.prnil.2025.03.005_bib6","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"337","author":"Driver","year":"2008","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.prnil.2025.03.005_bib7","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.juro.2014.12.027","article-title":"Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer","volume":"193","author":"Tsai","year":"2015","journal-title":"J Urol"},{"issue":"27","key":"10.1016\/j.prnil.2025.03.005_bib8","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.prnil.2025.03.005_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American heart association, American cancer society, and American urological association: endorsed by the American society for radiation oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0022-5347(01)67239-2","article-title":"Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia","volume":"154","author":"Eri","year":"1995","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.prnil.2025.03.005_bib11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2025.03.005_bib12","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.prnil.2025.03.005_bib13","doi-asserted-by":"crossref","first-page":"892335","DOI":"10.3389\/fcvm.2022.892335","article-title":"Etiology and management of dyslipidemia in patients with cancer","volume":"9","author":"de Jesus","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"10.1016\/j.prnil.2025.03.005_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239042","article-title":"Visceral obesity and its shared role in cancer and cardiovascular disease: a scoping review of the pathophysiology and pharmacological treatments","volume":"21","author":"Aparecida Silveira","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.prnil.2025.03.005_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-014-0474-5","article-title":"A review of statin use and prostate cancer","volume":"17","author":"Pon","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.prnil.2025.03.005_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.amepre.2023.11.009","article-title":"Trends in cardiovascular disease mortality rates and excess deaths, 2010-2022","volume":"66","author":"Woodruff","year":"2024","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030062","article-title":"Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors","volume":"7","author":"Mostaghel","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.prnil.2025.03.005_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41391-018-0045-x","article-title":"Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer","volume":"21","author":"Allott","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.prnil.2025.03.005_bib19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/ijc.23715","article-title":"Association between plasma cholesterol and prostate cancer in the PSA era","volume":"123","author":"Platz","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib20","first-page":"61","article-title":"Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort","volume":"21","author":"Mondul","year":"2010","journal-title":"Cancer Causes Control"},{"issue":"10","key":"10.1016\/j.prnil.2025.03.005_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046691","article-title":"Statin use and risk of prostate cancer: a meta-analysis of observational studies","volume":"7","author":"Bansal","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.prnil.2025.03.005_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","article-title":"Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer","volume":"1","author":"Harshman","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5534\/wjmh.2016.34.1.28","article-title":"Hypercholesterolemia is associated with a shorter time to castration-resistant prostate cancer in patients who have undergone androgen deprivation therapy","volume":"34","author":"Jeon","year":"2016","journal-title":"World J Mens Health"},{"issue":"1","key":"10.1016\/j.prnil.2025.03.005_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/JU.0000000000000494","article-title":"Serum lipids prior to starting androgen deprivation therapy and risk of castration resistant prostate cancer and metastasis: results from the SEARCH database","volume":"203","author":"Dambal","year":"2020","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.prnil.2025.03.005_bib25","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"9602","key":"10.1016\/j.prnil.2025.03.005_bib26","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.prnil.2025.03.005_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2018.11.033","article-title":"Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications","volume":"112","author":"Van Rompay","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888225000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:57:33Z","timestamp":1758128253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888225000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2287888225000364"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2025.03.005","relation":{},"ISSN":["2287-8882"],"issn-type":[{"type":"print","value":"2287-8882"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence of dyslipidemia in patients with prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}